Last updated on May 2018

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies


Brief description of study

To evaluate the effects of BIIB033 versus placebo on disability improvement over 72 weeks and to evaluate the effects of BIIB033 versus placebo on additional measures of disability improvement.

Clinical Study Identifier: TX204943

Contact Investigators or Research Sites near you

Start Over

Angela Aungst

University of South Florida-Morsani College of Medicine
Tampa, FL USA
  Connect »